ATE255896T1 - Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen - Google Patents

Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen

Info

Publication number
ATE255896T1
ATE255896T1 AT97926590T AT97926590T ATE255896T1 AT E255896 T1 ATE255896 T1 AT E255896T1 AT 97926590 T AT97926590 T AT 97926590T AT 97926590 T AT97926590 T AT 97926590T AT E255896 T1 ATE255896 T1 AT E255896T1
Authority
AT
Austria
Prior art keywords
neurological disorders
pyridylpiperazine
tetrahydropteridine
treatment
crf
Prior art date
Application number
AT97926590T
Other languages
English (en)
Inventor
Richard Gerald Wilde
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of ATE255896T1 publication Critical patent/ATE255896T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT97926590T 1996-05-23 1997-05-19 Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen ATE255896T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1819896P 1996-05-23 1996-05-23
PCT/US1997/008448 WO1997044038A1 (en) 1996-05-23 1997-05-19 Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders

Publications (1)

Publication Number Publication Date
ATE255896T1 true ATE255896T1 (de) 2003-12-15

Family

ID=21786748

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97926590T ATE255896T1 (de) 1996-05-23 1997-05-19 Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen

Country Status (14)

Country Link
US (3) US6083948A (de)
EP (1) EP0901374B1 (de)
JP (1) JP2000511183A (de)
AT (1) ATE255896T1 (de)
AU (1) AU739269B2 (de)
CA (1) CA2255650A1 (de)
DE (1) DE69726724T2 (de)
DK (1) DK0901374T3 (de)
ES (1) ES2213216T3 (de)
IL (1) IL127170A0 (de)
NZ (1) NZ332704A (de)
PT (1) PT901374E (de)
WO (1) WO1997044038A1 (de)
ZA (1) ZA973884B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1129091T3 (da) 1998-11-12 2002-11-04 Neurocrine Biosciences Inc Antagonister for CRF-receptorer og fremgangsmåder med relation dertil
CA2349904A1 (en) 1998-11-12 2000-05-18 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
US6531475B1 (en) * 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
EP1040831A3 (de) * 1999-04-02 2003-05-02 Pfizer Products Inc. Verwendung von Corticotropin Releasing Factor (CRF) Antagonisten zur Prophylaxe des plötzlichen Todes
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
AU7738000A (en) * 1999-09-30 2001-04-30 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
TWI271406B (en) * 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP1278751A1 (de) * 2000-05-01 2003-01-29 Bristol-Myers Squibb Pharma Company Tricyclische kondensierte pyridin- und pyrimidin-derivate als crf rezeptor antagonisten
JP2003533530A (ja) 2000-05-18 2003-11-11 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニスト
CZ2003159A3 (cs) * 2000-07-19 2004-02-18 Bristol-Myers Squibb Pharma Co. Ligand CRF2 pro kombinační terapii
AU2002246855B2 (en) * 2000-10-23 2005-12-22 Smithkline Beecham Corporation Novel compounds
HUP0304035A2 (hu) 2001-04-30 2004-04-28 Glaxo Group Limited Kortikotropin-releasing faktor (CRF) receptor antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
PL367771A1 (en) * 2001-05-21 2005-03-07 Neurocrine Biosciences Inc. Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists
KR20040103972A (ko) * 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
US7067658B2 (en) * 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
WO2006086464A2 (en) * 2005-02-10 2006-08-17 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
US8703099B2 (en) * 2005-02-24 2014-04-22 Dr Pharma Nova, Llc Registry method and control system for DEA schedule II-V medicines
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
UY29439A1 (es) * 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
JP2008535822A (ja) * 2005-03-25 2008-09-04 グラクソ グループ リミテッド 新規化合物
AU2006229995A1 (en) * 2005-03-25 2006-10-05 Glaxo Group Limited Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives
MX2008000811A (es) * 2005-07-28 2008-03-18 Squibb Bristol Myers Co Tetrahidro-1h-pitido[4,3-b]indoles substituidos como agonistas y antagonistas del receptor de serotonina.
US7795436B2 (en) * 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
EP2010542B1 (de) 2006-04-12 2012-01-25 Vertex Pharmaceuticals Incorporated 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
CN101479269A (zh) * 2006-06-23 2009-07-08 阿斯利康(瑞典)有限公司 蝶啶衍生物及其作为组织蛋白酶抑制剂的用途
MY152687A (en) 2008-04-15 2014-10-31 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
US8551996B2 (en) * 2009-02-20 2013-10-08 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
WO2011031965A1 (en) 2009-09-14 2011-03-17 Gilead Sciences, Inc. Modulators of toll-like receptors
MX2012003484A (es) 2009-09-25 2012-04-20 Vertex Pharma Metodos para preparar derivados de pirimidina utiles como inhibidores de proteina cinasa.
SG179207A1 (en) 2009-09-25 2012-04-27 Vertex Pharma Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
JP5784113B2 (ja) 2010-06-10 2015-09-24 ユニオン カーバイド ケミカルズ アンド プラスティックス テクノロジー エルエルシー チオビスフェノール酸化防止剤／ポリエチレングリコールブレンド
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
JP5848442B2 (ja) 2011-05-20 2016-01-27 ユニオン カーバイド ケミカルズ アンド プラスティックス テクノロジー エルエルシー チオビスフェノール系酸化防止剤／ポリエチレングリコールのブレンド
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
SI3166607T1 (sl) 2014-07-11 2023-01-31 Gilead Sciences, Inc. Modulatorji toličnih receptorjev za zdravljenje HIV-a
MY195016A (en) 2014-08-04 2023-01-03 Nuevolution As Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases
CN107074860B (zh) 2014-09-16 2022-07-15 吉利德科学公司 制备toll样受体调节剂的方法
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
JP6689297B2 (ja) 2015-07-23 2020-04-28 武田薬品工業株式会社 複素環化合物
WO2017056115A1 (en) * 2015-10-03 2017-04-06 Sun Pharma Advanced Research Company Limited Novel n-aryl containing fused heterocyclic compounds
CN114702495A (zh) 2015-11-20 2022-07-05 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
BR112022012205A2 (pt) 2019-12-20 2022-09-13 Nuevolution As Compostos ativos para receptores nucleares
CA3174252A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
JP7713954B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3127402A (en) * 1964-03-31 Y-oxopteridine derivatives
US4077955A (en) * 1977-02-17 1978-03-07 E. R. Squibb & Sons, Inc. Amino derivatives of 1,2,3,4-tetrahydro-2-oxopyrido[2,2-b]-pyrazine carboxylic acids and esters
EP0008864A1 (de) * 1978-08-15 1980-03-19 FISONS plc Pyridopyrazin- und Chinoxalinderivate, Verfahren zu ihrer Herstellung, und sie enthaltende pharmazeutische Zusammensetzungen
FI823156L (fi) * 1981-09-16 1983-03-17 Ciba Geigy Ag Foerfarande foer framstaellning av nya polycykliska polyazaheterocykler
US4510141A (en) * 1982-09-13 1985-04-09 Ciba-Geigy Corporation Tricyclic polyazaheterocycles for treating depression or anxiety
JPS5976086A (ja) * 1982-09-20 1984-04-28 ザ　ウエルカム　フアウンデ−シヨン　リミテツド プテリジン化合物
GB8318833D0 (en) * 1983-07-12 1983-08-10 Wellcome Found Chemical compounds
HU221425B (en) 1990-11-06 2002-10-28 Yamanouchi Pharma Co Ltd Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
US5198547A (en) * 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
TW274550B (de) * 1992-09-26 1996-04-21 Hoechst Ag
EP0764153A1 (de) * 1994-06-06 1997-03-26 Pfizer Inc. Substituierte pyrazole mit "corticotropin-releasing factor"-(crf) antagonistischer aktivität
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
ES2135062T3 (es) 1994-06-16 1999-10-16 Pfizer Pirazolo y pirrolopiridinas.
JP3273108B2 (ja) * 1994-09-21 2002-04-08 アサヒビール株式会社 新規ピリド〔２，３−ｄ〕ピリミジン誘導体及びその製造方法

Also Published As

Publication number Publication date
EP0901374A4 (de) 2001-05-09
DK0901374T3 (da) 2004-04-05
US20030064993A1 (en) 2003-04-03
WO1997044038A1 (en) 1997-11-27
AU3131697A (en) 1997-12-09
ES2213216T3 (es) 2004-08-16
AU739269B2 (en) 2001-10-11
NZ332704A (en) 2000-05-26
EP0901374A1 (de) 1999-03-17
JP2000511183A (ja) 2000-08-29
US6083948A (en) 2000-07-04
US6399609B1 (en) 2002-06-04
US6869955B2 (en) 2005-03-22
IL127170A0 (en) 1999-09-22
CA2255650A1 (en) 1997-11-27
ZA973884B (en) 1998-11-06
DE69726724T2 (de) 2004-12-09
PT901374E (pt) 2004-04-30
DE69726724D1 (de) 2004-01-22
EP0901374B1 (de) 2003-12-10

Similar Documents

Publication Publication Date Title
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
PT1049699E (pt) Pirazolotriazinas como antagonistas de flc
BR9307646A (pt) Pirrolopirimidinas como antagonistas de crf
LV12262A (lv) Ar arilaminu kondenseti piridini un pirimidini
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE213495T1 (de) Eine resorbierbare röntgenopake markierung enthaltendes chirurgisches implantat und verfahren zum verriegeln desselben in einem körper
ATE198706T1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
ATE307592T1 (de) Epiallopregnanolon zur behandlung von krankheiten des cns
DE69807085D1 (de) Heterocyclyl-substituierte annellierte pyridine und pyrimidine als antagonisten des corticotropin freisetzenden hormons (crh), verwendbar für die behandlung von cns und stress
ATE267013T1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit
DE69524623D1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE209910T1 (de) Verwendung von 6,7-substituierter 2- aminotetraline zur behandlung von zytokin- vermittleten entzündungszuständen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0901374

Country of ref document: EP

REN Ceased due to non-payment of the annual fee